The clonidine Lauriad is used to prevent radiotherapy-induced oral mucositis in patients with head and neck cancer.
BioAlliance Pharma COO Judith Greciet said the European designation for clonidine Lauriad as an orphan drug is key in shortening its development timeline, optimizing costs and reinforcing its future market access.